Antineuronal antibodies in patients with neuroblastoma: relationships with clinical features.
We evaluated the frequency of serum antineuronal antibodies in a cohort of 39 neuroblastoma patients and related their presence to clinical features. Twelve patients displayed antineuronal antibodies at immunocytochemistry. Only one of these 12 patients suffered from a clinically overt paraneoplastic syndrome. No significant differences emerged between autoantibody-positive and autoantibody-negative patients in terms of progression-free and overall survival, although when only patients evolving to disease progression were considered, the time interval between diagnosis and progression was slightly longer in autoantibody-positive patients.
Salmaggi
A
A
Istituto Nazionale Neurologico C. Besta, Milan, Italy.
Luksch
R
R
Forno
M G
MG
Pozzi
A
A
Silvani
A
A
Boiardi
A
A
Gasparini
M
M
Nemni
R
R
D000293:Adolescent; D001323:Autoantibodies / Q000097:blood*; D015153:Blotting, Western; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D008297:Male; D009447:Neuroblastoma / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D009474:Neurons / Q000276:immunology*; D010257:Paraneoplastic Syndromes; D016019:Survival Analysis
D001323:Autoantibodies